Investment Overview

PharmEasy is an unlisted company operating in the Health Care sector (E-Pharmacy & Healthtech). PharmEasy is an Indian digital healthcare platform operated by API Holdings that offers e-pharmacy, diagnostics, teleconsultation and health subscriptions. The platform connects consumers with licensed pharmacies and diagnostic labs, enabling medicine delivery, lab tests at home and electronic recor…

Strengths

• Sector Leadership: Largest digital healthcare platform by GMV (RedSeer, 2021).
• Pan-India Reach: Services available in 18,587+ PIN codes, including rural areas.
• Strategic Acquisitions: Thyrocare acquisition (66% stake) strengthened diagnostic capabilities.

Key Risks

• Reliable Losses: Negative EBITDA (-₹646 crore in 2024) and PAT (-₹2,533 crore in 2024).
• High Debt Burden: Borrowings surged to ₹4,098 crore in 2024, straining liquidity.
• Reliance on Funding: Dependent on equity injections to offset cash burn.

Valuation View

The current unlisted market price is ₹5.54 per share with a market capitalisation of approximately ₹9538 crore. The company is currently unlisted and investors should factor in illiquidity risk and longer holding horizons. Investors are advised to review the full financial data and consult an advisor before investing.